Price (90d)
$7.23Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $9.68M | $-250.64M | $-1.41 |
| 2024 | $3.92M | $-126.23M | $-0.47 |
| 2023 | $6.22M | $-95.90M | $-0.39 |
| 2022 | $26.91M | $28.32M | $-0.33 |
| 2021 | $14.27M | $-92.17M | $-0.47 |
Social Signal Score
Earnings
Thu, Nov 12(in 3 months)
Consensus estimate $0.09 per share
Typical surprise +33.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.05 vs $-0.01beat
- Wed, May 13$-0.02 vs $-0.03beat
- Wed, Mar 25$-0.01 vs $-0.10beat
- Thu, Nov 13$-0.11 vs $-0.08miss
- Tue, Aug 12$-0.11 vs $-0.14beat
- Wed, May 14$-0.07 vs $-0.08beat
Estimates and results for PGEN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
PGENhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newszacks.com·1d ago·Neutral
Are You Looking for a Top Momentum Pick? Why Precigen, Inc. (PGEN) is a Great Choice Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newsseekingalpha.com·7d ago·Negative
Precigen: Has To Grow Into Its Valuation Precigen surged 266% on PAPZIMEOS FDA approval but now trades at a premium valuation near $2.24 billion. PAPZIMEOS, the sole revenue driver, reached $53.1 million in Q2 with COGS being just around $2.8 million. PGEN's pipeline faces stiff competition, with most candidates showing weaker efficacy than approved or late-stage rivals.
View source ↗